Abstract
Introduction: In recent years, numerous pharmacological approaches for the treatment of type 2 diabetes mellitus (T2DM) have become available. While all of them have proven blood glucose-lowering effects, identifying the most beneficial drug or drug combination for the treatment of an individual patient has become an increasing challenge. Several guidelines attempt to provide decision criteria based on clinical characteristics and comorbidities in patients with T2DM, however, these guidelines still leave a broad range of capabilities for pharmacological treatment escalation.
Pathophysiological Approach: Addressing the pathophysiology of T2DM might be a valuable approach for the selection and combination of different drugs that can provide the most comprehensive effects in the treatment of T2DM. Besides decreasing insulin sensitivity, a progressing imbalance in alpha and beta cell function of the Langerhans islet is a fundamental component in the complex pathophysiology of the disease.
Conclusion: Considering the effect of different pharmacological interventions on the pathophysiological components in T2DM might be an effective tool guiding to most beneficial treatments, and may lead to a more tailored pharmacological intervention in patients with T2DM. .
Keywords: Type 2 Diabetes mellitus, pathophysiology, insulin resistance, alpha cell function, beta cell function, treatment of T2DM.
Current Diabetes Reviews
Title:Pharmacological Intervention in Type 2 Diabetes Mellitus – A Pathophysiologically Reasoned Approach?
Volume: 12 Issue: 4
Author(s): Thomas Forst, Tim Heise and Leona Plum-Morschel
Affiliation:
Keywords: Type 2 Diabetes mellitus, pathophysiology, insulin resistance, alpha cell function, beta cell function, treatment of T2DM.
Abstract: Introduction: In recent years, numerous pharmacological approaches for the treatment of type 2 diabetes mellitus (T2DM) have become available. While all of them have proven blood glucose-lowering effects, identifying the most beneficial drug or drug combination for the treatment of an individual patient has become an increasing challenge. Several guidelines attempt to provide decision criteria based on clinical characteristics and comorbidities in patients with T2DM, however, these guidelines still leave a broad range of capabilities for pharmacological treatment escalation.
Pathophysiological Approach: Addressing the pathophysiology of T2DM might be a valuable approach for the selection and combination of different drugs that can provide the most comprehensive effects in the treatment of T2DM. Besides decreasing insulin sensitivity, a progressing imbalance in alpha and beta cell function of the Langerhans islet is a fundamental component in the complex pathophysiology of the disease.
Conclusion: Considering the effect of different pharmacological interventions on the pathophysiological components in T2DM might be an effective tool guiding to most beneficial treatments, and may lead to a more tailored pharmacological intervention in patients with T2DM. .
Export Options
About this article
Cite this article as:
Forst Thomas, Heise Tim and Plum-Morschel Leona, Pharmacological Intervention in Type 2 Diabetes Mellitus – A Pathophysiologically Reasoned Approach?, Current Diabetes Reviews 2016; 12 (4) . https://dx.doi.org/10.2174/1573399812666160613111959
DOI https://dx.doi.org/10.2174/1573399812666160613111959 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Development, Optimization & Evaluation of Porous Chitosan Scaffold Formulation of Gliclazide for the Treatment of Type-2 Diabetes Mellitus
Drug Delivery Letters The Role of TNF and Its Family Members in Inflammation and Cancer: Lessons from Gene Deletion
Current Drug Targets - Inflammation & Allergy The Metabolic Syndrome and Chronic Liver Disease
Current Pharmaceutical Design Increasing High-Density Lipoprotein Cholesterol Through Cholesteryl Ester Transfer Protein Inhibition: A Next Step in the Fight Against Cardiovascular Disease?
Current Drug Targets - Cardiovascular & Hematological Disorders Natural Product-Inspired Synthesis of Thiazolidine and Thiazolidinone Compounds and their Anticancer Activities
Current Pharmaceutical Design Endothelin-1 and Human Platelets
Current Vascular Pharmacology Hepatic Elimination of Drugs in Gestational Diabetes
Current Clinical Pharmacology Nutraceuticals for Promoting Longevity
Current Nutraceuticals Chronic Exposure to Low-Level Cadmium in Diabetes: Role of Oxidative Stress and Comparison with Polychlorinated Biphenyls
Current Drug Targets Can Lipoprotein-associated Phospholipase A<sub>2</sub> be Used as a Predictor of Long-term Outcome in Patients with Acute Coronary Syndrome?
Current Cardiology Reviews Urotensin II: A Vascular Mediator in Health and Disease
Current Vascular Pharmacology Seaweed Proteins as a Source of Bioactive Peptides
Current Pharmaceutical Design Ion Channels as Therapeutic Targets for Type 1 Diabetes Mellitus
Current Drug Targets Recent Developments in the Discovery of Novel Antipsychotic Agents Modualating Dopamine and Serotonin Receptors
Current Drug Targets Genetic Variability of Matrix Metalloproteinase Genes in Cardiovascular Disease
Current Topics in Medicinal Chemistry Mean Platelet Volume: A Link Between Thrombosis and Inflammation?
Current Pharmaceutical Design Interactions Between Plasma Proteins and Naturally Occurring Polyphenols
Current Drug Metabolism A Comparative Summary on Antioxidant-like Actions of Timolol with Other Antioxidants in Diabetic Cardiomyopathy
Current Drug Delivery Editorial (Thematic Issue: Global Trends in Nanotechnological Approaches for Various Health Issues – Volume II)
Current Drug Metabolism Angiogenesis as a Therapeutic Target in Arthritis: Lessons from Oncology
Current Pharmaceutical Design